Shenzhen Salubris Pharmaceuticals stock
002294.SZSHZShenzhen Salubris Pharmaceuticals Co., Ltd., HealthcareISIN CNE100000FW8
52Score 52 out of 100, Neutral
Price and trend
32 / 100
Price history
−50% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 27% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 39).
The price is 56% below its 52-week high. Largest decline in 17 years: 68% (April 2010 to January 2012).
Chart figures for advanced users
- SMA 50$4.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.09
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)39
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.44
- The lowest closing price of the last twelve months.
- Resistance$10.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- In fiscal 2025 it reported revenue of $645.86M (up 7.3% year on year) and earnings of $97.7M (up 8.3%).
- MEQIRI Score 52 out of 100 (Neutral): rank 357 of 703 in Healthcare, median 53.
- The P/E is 46.2 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 54.6).
Show more
- Our model puts fair value at $1.96, with the price 128% above it.
Strengths
- Earnings per share growingUp 57.8% a year since 2020.Growth 65
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 65
- More cash than debtCash $239.23M, financial debt $144.88M.Stability 81
Weaknesses
- Above fair valuePrice 128% above the fair value of $1.96.Valuation 23
- Share price fell sharplyDown 48% over the last 12 months.Momentum 20
- Volatile share priceVolatility 51% a year over the last 12 months.
Its standout strength is stability, while valuation and momentum hold the score back.
computed just now
How the score is calculatedScore overview
Score since yesterday from 53 to 52.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $1.40 and expensive above $3.27 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $0.78 (cash-flow model) and $3.14 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $1.90, at 6.3% it would be $2.06.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.1% on the twelve months before. Revenue has grown strongly since 2006, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 73%, operating 15%, net 15%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 30 Mar 2027in 137 days
- Last reported
- 26 Oct 2026EPS reported $0.03
Analyst estimates
Earnings estimates have barely changed since 27 Oct 2026.
- Earnings per share
- $0.11−1.7%
- Revenue
- $792.52M−0.3%
- Earnings per share
- $0.15−1.9%
- Revenue
- $954.22M−0.2%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Shenzhen Salubris Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
703 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
ETFs that hold Shenzhen Salubris Pharmaceuticals
Held by 38 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Market Access Stoxx China A Minimum Variance Index UCITS ETFM9SV | 0.44% | 0.45% | €284.44M |
| HSBC MSCI China A UCITS ETF USDH41K | 0.13% | 0.30% | €68.31M |
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.08% | 0.65% | €251.68M |
Show 5 more
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.07% | 0.65% | €10.81M |
| WisdomTree Emerging Markets SmallCap Dividend UCITS ETFWTED | 0.05% | 0.54% | €35.5M |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.43B |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.01% | 0.30% | €132.6M |
| iShares MSCI China UCITS ETFICGA | 0.01% | 0.28% | €2.21B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jul 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.